ClinicalTrials.gg
Status unknownNCT04206007Updated Dec 4, 2023

Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease

A Phase 1 interventional study of UMC119-06 in Chronic Obstructive Pulmonary Disease Moderate, sponsored by Meridigen Biotech Co., Ltd.. Status unknown at 1 site in Taiwan. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-12-04.

Sponsored by Meridigen Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 157 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan — 27 open to participants now, 29 under way, 5 of them phase 3. Pulmonary Disease, Chronic Obstructive · Taiwan.

Planned enrollment
119th of 123
9 · median 137
Started
2020
with 8 others
Phase 1
6 of 157
1 open now
Registered
87th of 157
by date

Among the 157 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, this one is the 119th largest by planned enrollment of the 123 interventional ones that give a count, is one of 9 that started in 2020, is one of 6 in phase 1, and was the 87th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

27 of the 157 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 157 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, or all of them as a file.
02

Study summary

The clinical study with UMC119-06 is designed to investigate the safety in patients with Chronic Obstructive Pulmonary Disease. This will be a dose escalation, open label, single-center study in adult with chronic obstructive pulmonary disease. UMC119-06 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of chronic obstructive pulmonary disease.

Read the detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, predicted to be the third leading cause of death in adults by 2020. Patients with COPD are characterized with airflow limitation and chronic inflammation, which is caused by cigarette smoking, noxious particles or gases. These inhaled irritants will induce inflammation, emphysema and fibrosis though chronic exposure. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β2-adrenergic agonists (short-and long-acting), anticholinergics, theophylline, or a combination of these drugs. In patients with continuing exacerbations, inhaled corticosteroids (ICSs) may be added in the form of a triple fixed dose combination inhaler that includes ICSs, long-acting β2-agonists (LABA) and inhaled long-acting muscarinic antagonists (LAMA). Although current clinical treatment strategies can improve and stabilize COPD states and quality of life, none of them are able to modify the progressive decline in lung function which is the hallmark of this disease. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of COPD in adult patients is of urgent need. Among the more innovative, experimental therapies, mesenchymal stromal cells (MSCs) are proposed as a novel therapy with potential in treatment of COPD.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease Moderate

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of age between ≥ 40 through ≤ 75 years.
  • Subjects with diagnosis of based on the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) standard.
  • Subjects with a post-bronchodilator /FVC ratio \<0.7.
  • Subjects with a post-bronchodilator FEV1 % predicted value ≥ 50% and \< 80%.
  • Subjects with score ≥ 2 in the modified Medical Research Council Dyspnea Scale (mMRC).
  • Subjects with in COPD Assessment Test (CAT) score ≥ 10.
  • Subjects with body weight between 40 to 90 kg.
  • Subject is willing to provide written to participate in the study after reading the informed consent form and the information provided.
  • Women of should have a negative urine pregnancy test prior to administration of product, UNLESS they meet the following criteria:

    1. : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40 mIU/m, OR;
    2. 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy
  • If a male and heterosexually active with a female of childbearing potential, the subject must agree to use a double barrier method of (or must have been surgically sterilized) and to not donate sperm during the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects with history of any type of .
  • Subjects with major surgery (body organs that require anesthesia, such as tumor removal, open chest, heart surgery, abdominal surgery, intracranial surgery, or normal surgery for more than 3 hours, etc.) within previous 30 days.
  • Subjects who are pregnant (or plan to become pregnant within 3 months of product treatment) or lactating.
  • Subjects who have a significant concomitant illness as judged by principal investigator (PI).
  • Subjects with known infection or who are immune compromised.
  • Subjects with a known history of alcohol abuse or drug abuse within the 5 years before study treatment administration.
  • Subjects who are current smokers.
  • Subjects unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation.
  • Subjects with a history of severe allergic or anaphylactic reactions.
  • Subjects with known allergy or to any component of the formulation or hypersensitivity to any component of the formulation (normal saline and human serum albumin).
  • Subjects who have participated in another clinical study of new investigational therapies or have received an investigational therapy within the 12 weeks before study drug administration.
  • Subjects with known Alpha-1 antitrypsin deficiency.
  • Subjects with current active infection including pulmonary infection, systemic infection or severe local infections.
  • Subjects with exacerbation of within the 12 weeks before study treatment administration.
  • Subjects who have the following conditions in laboratory tests at screening;

    1. >2 × (ULN) for (ALT) or aspartate aminotransferase (AST); or
    2. >2 × ULN for serum creatinine.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    UMC119-06

    Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.

    Biological: UMC119-06

Interventions

  • BiologicalUMC119-06

    Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06

06

What researchers measure

Primary outcomes

  1. The incidence and frequency of adverse events related to administration of UMC119-06.

    * Incidence of Treatment-Emergent Adverse Events (TEAEs). * Incidence of withdrawals due to Adverse Events(AEs).

    Time frame: 3 months from the day of administration

Secondary outcomes

  1. Changes in Forced Vital Capacity (FVC).

    Improvement in clinical function as assessed by mean change in Forced Vital Capacity (FVC).

    Time frame: 15 months from the day of administration.

  2. Changes in Forced Expiratory Volume in One Second (FEV1).

    Improvement in clinical function as assessed by mean change in Forced Expiratory Volume in One Second (FEV1).

    Time frame: 15 months from the day of administration.

  3. Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).

    Improvement in clinical function as assessed by mean change in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).

    Time frame: 15 months from the day of administration

  4. Changes in exercise performance using 6-min walk test (6MWT).

    Improvement in clinical function as assessed by mean change in exercise performance using 6-min walk test (6MWT).

    Time frame: 15 months from the day of administration.

  5. Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).

    Scores range from 0 (no impairment) to 100 (maximum impairment), with higher scores indicating more limitation. A decrease in score represents a decrease in disease related symptoms. Improvement in clinical function as assessed by mean change in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).

    Time frame: 15 months from the day of administration.

  6. Changes in modified medical research council (mMRC) -dyspnea scale.

    Scores range from 0 (no dyspnea) to 4 (severe dyspnea), with higher scores indicate worse COPD control. Improvement in clinical function as assessed by mean change in modified medical research council (mMRC) -dyspnea scale.

    Time frame: 15 months from the day of administration.

07

Study locations

1 site
  • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare.
    New Taipei City, 23561, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2023, 42 months after the start.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 42 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2019
First posted
Dec 20, 2019
StartActual
Jun 11, 2020
Primary completionEst.
Dec 31, 2023
CompletionEst.
Jun 30, 2024
Last update
Dec 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04206007
Lead sponsor
Meridigen Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Dec 20, 2019
Start date
Jun 11, 2020
Primary completion
Dec 31, 2023 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Dec 4, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion